Literature DB >> 22210101

In vivo inferiority of generic product compared with branded vancomycin: a paradigm shift.

G W 't Jong1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22210101     DOI: 10.1097/FTD.0b013e318243e739

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


× No keyword cloud information.
  1 in total

1.  Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.